BEIJING, Dec. 22,
2022 /PRNewswire/ -- WeTrade Group Inc.
("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified
"software as a service" ("SaaS") technology service provider
committed to providing technical support and digital transformation
tools for enterprises across different industries, today announced
that the cooperation with Jiqing Biomedical Technology Co.
Ltd. ("Jiqing Biotech") has reached a milestone
achievement in that Jiqing Biotech's
COVID-19 self-test kit has been sold up to 1 million units per day
in China with the help of Wetrade
Group's multi-dimensional marketing tool, SaaS.
With the gradual loosening of domestic pandemic prevention
policies, the self-use of antigen products has expanded, allowing
it to gradually transition from being a medical and professional
item to an over-the-counter consumer product projected with a
sizeable increase in market demand.
The accuracy of the Jiqing Biotech's COVID-19 antigen
self-test kit exceeds 98%, and guarantees a rapid and accurate
result within 15 minutes. It will facilitate the needs for rapid
self-testing at home, and will serve to better meet the needs of
COVID detection, prevention and control around the
world.
The cooperation between Wetrade Group and Jiqing Biology
began in August. Wetrade Group not only helps Jiqing Biotech develop
in domestic and foreign sales channels through cooperation, but
also contributes to the medical industry in general by investing in
Jiqing
Biotech. After cooperating with
Jiqing, Wetrade Group has successively reached cooperation with
Parkway Medical Limited, MobiLab Medical Innovatives, Zhixun
Biotechnology Limited, among others. Up to now, Wetrade Group has
formed three business segments represented by YCloud, WTPay and
Y-Health.
Y-Health is a global public health business segment
launched by Wetrade Group, and it focuses on facilitating global
business of bio-health companies. At present, Y-Health mainly
focuses on covid-19 detection and prevention, daily health,
traditional Chinese medicine. This achievement signifies an
official and successful entry of Wetrade Group into the medical
field.
About WeTrade Group Inc.
WeTrade Group Inc. is a global diversified "software as a
service" ("SaaS") technology service provider which is committed to
providing technical support and digital transformation tools for
enterprises across different industries. The three main business
segments of the Company are YCloud, WTPay and Y-Health.
YCloud is a micro-business cloud intelligent system
launched by WeTrade, serving global micro-business industry. YCloud
strengthens users' marketing relationship and CPS commission profit
management through leading technology and big data analysis. It
also helps increase the payment scenarios to increase customers'
revenue by multi-channel data statistics, AI fission and management
as well as improved supply chain system.
Independently developed by the Company, WTPay supports
multiple methods of online payment and eight mainstream digital
wallets in over 100 countries to help customers quickly realize
global collection and payment business. Customers can use WTpay for
global acquiring business, global store opening, global payment
collection, international banking, global remittance and currency
exchange.
Under its global public health business sector Y-Health,
the Company engages in developing global business for biological
health and medical enterprises. Currently, Y-Health mainly focuses
on detection and prevention of epidemic, daily healthcare,
traditional Chinese medicines, and others.
For more information, please
visit https://ir.wetg.group.
Forward-Looking Statements
This press release contains information about the
Company's view of its future expectations, plans and prospects that
constitute forward-looking statements. Actual results may
differ materially from historical results or those indicated by
these forward-looking statements as a result of a variety of
factors including, but not limited to, risks and uncertainties
associated with its ability to raise additional funding, its
ability to maintain and grow its business, variability of operating
results, its ability to maintain and enhance its brand, its
development and introduction of new products and services, the
successful integration of acquired companies, technologies and
assets into its portfolio of products and services, marketing and
other business development initiatives, competition in the
industry, general government regulation, economic conditions,
dependence on key personnel, the ability to attract, hire and
retain personnel who possess the technical skills and experience
necessary to meet the requirements of its clients, and its ability
to protect its intellectual property. The Company's encourages
you to review other factors that may affect its future results in
the Company's annual reports and in its other filings with the
Securities and Exchange Commission.
View original
content:https://www.prnewswire.com/news-releases/wetrade-group-y-health-celebrates-the-daily-sale-of-jiqing-biotech-covid-19-antigen-kit-to-reach-1-million-301709053.html
SOURCE WeTrade Group INC